2.23 Question of the Week & Ethics and Inefficiencies of Clinical Trials with Dr. Jonathan Kimmelman

Plenary Session

English - November 20, 2019 18:21 - 58 minutes - 55.4 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 2.22 Question of the Week & EMR, Talking to Patients, and Being a Doctor with Dr. Robert Hirschtick

Next Episode: 2.24 Questions of the Week: the USMLE Step 2 CK, Hematology/Oncology, & One From a Med Student

First up this week is Question of the Week inspired by the Hematology/Oncology boards, with Dr. Sven Olson. No monologue on current trials this week because our host is still in Australia, so we conclude the episode with an interview with Dr. Jonathan Kimmelman of McGill University on his extensive work in research ethics, studying the most important issue in cancer medicine today: the risk-benefit of clinical trials and how best to spare patients from the burdens of creating a new drug.

Review of Sunitinib: doi.org/10.1093/jnci/djv292
Benefit, Burden, and Impact: doi.org/10.1177/1740774519873883

Back us on Patreon! www.patreon.com/plenarysession